Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Snoring as a Risk Factor for Sexual Dysfunction in Community Men
Hanak, Viktor, Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Lieber, Michael M., Olson, Eric J. , Gades, Naomi M. , Jacobsen, Steven J. , Somers, Virend K. , St Sauver, Jennifer L

Mayo Clinic

The Journal of Sexual Medicine | March 26, 2008 | Volume: 5 | Issue: 4 | Pages: 898-908

10.1111/j.1743-6109.2007.00706.x | PMID 18086163 Get It

ABSTRACT Introduction Severe obstructive sleep apnea has been associated with sexual dysfunction; however, it is unclear whether milder forms of sleep disturbances might also be associated with sexual problems. Aim To evaluate the association between snoring and five measures of sexual dysfunction in a population-based sample of men. Methods A stratified random sample of men residing in Olmsted County, Minnesota completed a questionnaire containing questions from the Brief Male Sexual Function Inventory (BMSFI) and a sleep questionnaire. Main Outcome Measures Levels of sexual drive (libido), erectile function, ejaculatory function, sexual problem assessment, and sexual satisfaction as assessed by the BMSFI. Results Of 827 men with a regular sexual partner, subjects were divided into categories of heavy (N=95), moderate (N=573), and none/mild (N=159) snoring. Their median age was 64 years (range 51–90). The sexual satisfaction domain score was significantly lower in the heavy snoring group (P value=0.01). The odds of low sexual satisfaction was 2.3 (95% CI 1.2, 4.1) among the heavy snorers compared with the none/mild snoring group. This association remained statistically significant after adjustment for smoking, medical comorbidities, and mental health status. However, there was no significant difference in ejaculatory function, erectile function, sexual drive, and sexual problem assessment across snoring categories. Conclusions These data provide evidence of an association between snoring severity and reduced sexual satisfaction in a population of elderly community males. Snoring was not associated with biologic measures of sexual dysfunction.
Associations Between Diabetes and Clinical Markers of Benign Prostatic Hyperplasia Among Community-Dwelling Black and White Men
Sarma, Aruna V. , Burke, J. P., Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Lieber, Michael M., Herman, William, Montie, James E. , Jacobsen, Steven J. , Girman, Cynthia J. , Macoska, Jill A. , St Sauver, Jennifer L

Mayo Clinic

Diabetes Care | February 28, 2008 | Volume: 31 | Issue: 3 | Pages: 476-482

10.2337/dc07-1148 | PMID 18071006 Get It

OBJECTIVE—The aim of this study was to examine associations between diabetes and clinical markers of benign prostatic hyperplasia (BPH) in community-dwelling white and black men aged 40–79 years. RESEARCH DESIGN AND METHODS—Data from the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study were combined for a total study sample of 2,484 men. Severity of lower urinary tract symptoms (LUTS), peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA) levels were examined by self-reported physician-diagnosed diabetes. RESULTS—Overall, 170 men (6.8%) reported a history of diabetes. Increased irritative LUTS and specifically nocturia were positively associated with diabetes. These patterns were consistent across race and persisted after adjustment for age, BMI, and various indicators of socioeconomic status. Furthermore, the relationship between irritative LUTS and diabetes was greater in black men. No significant associations were observed between diabetes and prostate volume, PSA level, and peak urinary flow rate. CONCLUSIONS—Our multiethnic community-based study demonstrates positive associations between diabetes and irritative LUTS and nocturia. Moreover, the association between irritative LUTS and diabetes is increased in black men. There was no strong evidence for an association between diabetes and BPH across measures more specific to BPH (i.e., prostate volume, PSA, and peak urinary flow rate). Taken together, our findings suggest that the presence of diabetes may be less related to prostate growth and more related to the dynamic components of lower urinary tract function. Further evaluations of the association between diabetes and BPH and related racial variations are warranted.
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein
Park, Laibaik , Zhou, Ping , Pitstick, Rose, Capone, Carmen, Anrather, Josef , Norris, Erin H. , Younkin, Linda H., Younkin, Steven G. , Carlson, George A. , McEwen, Bruce S. , Iadecola, Costantino

Mayo Clinic

Proceedings of the National Academy of Sciences | January 17, 2008 | Volume: 105 | Issue: 4 | Pages: 1347-1352

10.1073/pnas.0711568105 | PMID 18202172 Get It

Alterations in cerebrovascular regulation related to vascular oxidative stress have been implicated in the mechanisms of Alzheimer's disease (AD), but their role in the amyloid deposition and cognitive impairment associated with AD remains unclear. We used mice overexpressing the Swedish mutation of the amyloid precursor protein (Tg2576) as a model of AD to examine the role of reactive oxygen species produced by NADPH oxidase in the cerebrovascular alterations, amyloid deposition, and behavioral deficits observed in these mice. We found that 12- to 15-month-old Tg2576 mice lacking the catalytic subunit Nox2 of NADPH oxidase do not develop oxidative stress, cerebrovascular dysfunction, or behavioral deficits. These improvements occurred without reductions in brain amyloid-β peptide (Aβ) levels or amyloid plaques. The findings unveil a previously unrecognized role of Nox2-derived radicals in the behavioral deficits of Tg2576 mice and provide a link between the neurovascular dysfunction and cognitive decline associated with amyloid pathology.
Screening for Biotinidase Deficiency in Children with Unexplained Neurologic or Developmental Abnormalities
Sutherland, Steven J., Olsen, Richard D., Michels, Virginia V., Schmidt, Michael A. , O’Brien, John F.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 30 | Issue: 2 | Pages: 81-84

10.1177/000992289103000203 | PMID 1706649 Get It

To test the hypothesis that the frequency of biotinidase deficiency is greater in children with unexplained developmental delay or neurologic abnormalities than in the general population, we studied children seen at a large outpatient clinic over a four-year period who had one or more of these neurologic abnormalities and for whom no specific cause for their abnormalities could be found. The group totaled 274 children (163 boys; 111 girls) whose ages ranged from 2 weeks to 17 years. Characteristics were IQ/DQ, 30 to 70 in the 115 for whom scores were available; 41% had seizures; 15% had sensorineural hearing loss; 54% showed gross motor delay or ataxia; and 27% had decreased muscle tone. One patient with a classical clinical picture of biotinidase deficiency was diagnosed during the study period and was not included in the study. None of the patients with nonclassic findings had a deficiency of biotinidase activity. Our results suggest that biotinidase deficiency does not account for a large proportion of children with unexplained neurologic abnormalities or developmental delay. This does not negate the importance of biotinidase testing in children with clinical patterns specifically suggestive of the deficiency.
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, Shaji , Rajkumar, S. Vincent , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Dingli, David , Lust, John A., Greipp, Philip R., Kyle, Robert A. , Buadi, Francis K. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | November 2, 2007 | Volume: 111 | Issue: 5 | Pages: 2516-2520

10.1182/blood-2007-10-116129 | PMID 17975015 Get It

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem-cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P < .001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P < .001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.
Plasma amyloid β protein is elevated in late-onset Alzheimer disease families
Ertekin‐Taner, Nilüfer , Younkin, Linda H., Yager, Debra, Parfitt, Francine, Younkin, Steven G. , Graff‐Radford, Neill R. , Baker, Matthew , Asthana, Sanjay , Hutton, M.

Mayo Clinic

Neurology | October 3, 2007 | Volume: 70 | Issue: 8 | Pages: 596-606

10.1212/01.wnl.0000278386.00035.21 | PMID 17914065 Get It

Editorial Comment
Petrou, Steven

Mayo Clinic

Journal of Urology | August 15, 2007 | Volume: 178 | Issue: 4 | Pages: 1332-1332

10.1016/j.juro.2007.05.260 Get It

Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741
Dy, Grace K. , Krook, James E., Sargent, Daniel J. , Delaunoit, Thierry , Morton, Roscoe F., Fuchs, Charles S. , Ramanathan, Ramesh K., Williamson, Stephen K. , Findlay, B., Pockaj, Barbara A. , Pitot, Henry C., Goldberg, Richard M. , Green, Erin M. , Sticca, Robert P. , Alberts, Steven R. , Sargent, Daniel J , Williamson, Stephen

Mayo Clinic

Journal of Clinical Oncology | August 8, 2007 | Volume: 25 | Issue: 23 | Pages: 3469-3474

10.1200/jco.2007.10.7128 | PMID 17687151 Get It

Purpose To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach. Patients and Methods Data were collected retrospectively from CRC patients enrolled onto the phase III trial N9741, a National Cancer Institute–funded and Gastrointestinal Cancer Intergroup–sponsored study coordinated by the North Central Cancer Treatment Group. Patients were randomly assigned to combinations of oxaliplatin, fluorouracil (FU)/leucovorin (LV) and irinotecan. The three treatment arms consist of IFL (irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin). Median follow-up was 42.6 months. Results Sixty-two (4%) of 1,508 patients had a CR to chemotherapy alone, and an additional 32 (2%) had a CR after multimodality treatment. Factors associated with achieving CR with systemic chemotherapy alone included FOLFOX4 treatment, patients with assessable disease, or a single site of metastasis. Continuing protocol treatment beyond two cycles after documentation of CR was not associated with improved survival. The rate of curative intent resection was significantly higher for patients treated with oxaliplatin-containing regimens (P = .02). Median survival was similar between patients with CR after chemotherapy alone (44.3 months) or after multimodality approach (47.4 months; P = .81). Conclusion FOLFOX4 was more likely to produce a CR than were IFL or IROX. Oxaliplatin regimens were more likely to result in successful surgical resections. Patients who have CR to systemic chemotherapy alone can achieve impressive survival outcomes similar to those seen among patients who attained a CR status after multimodality treatment.
Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53)
Schild, Steven E. , Bonner, James A. , Hillman, Shauna L., Kozelsky, Timothy F., Vigliotti, Antonio P., Marks, Randolph S., Graham, David L. , Soori, Gamini S. , Kugler, John W., Tenglin, Richard C., Wender, Donald B., Adjei, Alex A. , Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | July 18, 2007 | Volume: 25 | Issue: 21 | Pages: 3124-3129

10.1200/jco.2006.09.9606 | PMID 17634491 Get It

Purpose To evaluate the outcome of patients with limited-stage small-cell lung cancer (L-SCLC) treated with cisplatin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily thoracic radiotherapy (bid RT). Patients and Methods A total of 76 assessable patients were treated on this phase II trial, which included six cycles of PE. PCI (25 Gy/10 fractions) was delivered during cycle 3 to responding patients. Cycles 4 and 5 included concurrent chemotherapy and thoracic RT (30 Gy/20 bid fractions, a 2-week break, and another 30 Gy/20 bid fractions). Results Of the 76 assessable patients, 74 patients (97%) suffered grade 3 or greater (3+) toxicity and 61 patients (80%) had grade 4 or greater (4+) toxicity. Of these adverse events, grade 3+ hematologic toxicity occurred in 72 patients (95%), and grade 3+ nonhematologic toxicity occurred in 55 patients (72%). Only one (2%) of the 61 patients who received PCI experienced treatment failure in the brain. The 5-year survival rate of the 76 assessable patients was 24% (median, 20 months). The 5-year survival rate of the 64 patients who received thoracic RT was 29% (median, 22 months). The 5-year cumulative incidence of in-field treatment failure was 34%. Conclusion This regimen included a high total dose of bid TRT, which resulted in a favorable 5-year survival rate. Local failure remains a problem that will require additional investigation. Newer technology should allow the safe administration of greater doses of RT, which should improve patient outcome. Data from eight trials were combined to demonstrate a relationship between RT dose fractionation and 5-year survival.
Transfusion-related Acute Lung Injury in the Critically Ill
Rana, Rimki, Winters, Jeffrey L. , Yılmaz, Murat , Méndez, José L. , Rickman, Otis B. , O’Byrne, Megan M., Evenson, Laura K., Malinchoc, Michael, DeGoey, Steven R., Afessa, Bekele, Hubmayr, Rolf D., Moore, S. Breanndan, Gajic, Ognjen , Winters, Jeffrey L

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 12, 2007 | Volume: 176 | Issue: 9 | Pages: 886-891

10.1164/rccm.200702-271oc | PMID 17626910 Get It

Abstract Rationale Acute lung injury (ALI) that develops 6 hours after transfusion (TRALI) is the leading cause of transfusion-related mortality. Several transfusion characteristics have been postulated as risk factors for TRALI, but the evidence is limited to retrospective studies. Objectives To compare patient and transfusion risk factors between patients who do and do not develop ALI. Methods In this prospective cohort study, consecutive transfused critically ill patients were closely observed for development of ALI. Donor samples were collected from the transfusion bags. Risk factors were compared between patients who developed ALI after transfusion and transfused control patients, matched by age, sex, and admission diagnosis. Measurements and Main Results Seventy-four of 901 transfused patients developed ALI within 6 hours of transfusion (8%). Compared with transfused control subjects, patients with ALI were more likely to have sepsis (37 vs. 22%, P = 0.016) and a history of chronic alcohol abuse (37 vs. 18%, P = 0.006). When adjusted for patient characteristics, transfusion of plasma from female donors (odds ratio [OR], 5.09; 95% confidence interval [95% CI], 1.37–18.85) rather than male donors (OR, 1.60; 95% CI, 0.76 to 3.37), number of pregnancies among the donors (OR, 1.19; 95% CI, 1.05 to 1.34), number of donor units positive for anti-granulocyte antibodies (OR, 4.85; 95% CI, 1.32–17.86) and anti–HLA class II antibodies (OR, 3.08; 95% CI, 1.15–8.25), and concentration of lysophosphatidylcholine in the donor product (OR, 1.69; 95% CI, 1.10 to 2.59) were associated with the development of ALI. Conclusions Both patient and transfusion risk factors determine the probability of ALI after transfusion. Transfusion factors represent attractive targets for the prevention of ALI.